retatrutide and mounjaro ESC 2024: improves lipid cardiovascular risk profile in Phase II trial CutKilo | Retatrutide - what

Badorrek et al., 2024)

Most physicians recommend choosing one pathway: phentermine (short-term, stimulant-based) or GLP-1 therapy (sustained, non-stimulant)

l nhng tri cy c cha lng ln inositol

Wegovy (semaglutide 2.4 mg) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity

GLP-1 plays a vital role in regulating several physiological processes, including: Appetite and satiety GLP-1 slows gastric emptying and increases feelings of fullness, reducing calorie intake